The University of Chicago is a leader in the treatment of testes cancer. When surgery is indicated, urologists at the University of Chicago specialize in the latest techniques to treat testes tumors, including orchiectomy as well as open and robotic retroperitoneal lymph node dissection (RPLND).
Testes cancer is a common cancer among young American men. Fortunately, approximately 95 percent of patients with testes cancer will be cured of their disease. Treatment options for testes cancer are dependent upon several factors, such as the type of testes cancer and the extent of disease. Treatments can include surgery, radiotherapy, chemotherapy or a combination of these approaches.
At the University of Chicago Medicine, our highly experienced testes cancer team specializes in the treatment of testes cancer and will gladly spend the time necessary to answer any questions and concerns you or your patients may have. Surgeons at the University of Chicago perform nerve-sparing RPLNDs, when oncologically appropriate, so that normal reproduction can occur after treatment is complete. Our surgeons also offer robotic RPLND surgery for select patients.